If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
210
results.
Updated on
21/02/2026 [06:51:00]
Absstract of: WO2026039780A1
Empty lipid nanoparticles free of PEG lipids are disclosed, along with methods of producing empty lipid nanoparticles. Loaded lipid nanoparticles produced using the empty lipid nanoparticles are disclosed, along with methods of producing the same. Lipid nanoparticles with no core polymeric lipid (e.g, PEG lipid) achieve stability, encapsulation efficiency, and in vitro protein expression on par with lipid nanoparticles having core polymeric lipids (e.g, PEG lipids).
Absstract of: AU2024293559A1
Provided is a diester lipid compound of Formula (I) or a pharmaceutically acceptable salt thereof The compound can be used to obtain lipid nanoparticles. In some embodiments, the lipid nanoparticle can comprise (a) from about 40 to about 100 mol % of the compound of Formula (I); (b) from 0 to about 10 mol % of a neutral lipid; (c) from 0 to about 50 mol % of a helper lipid; (d) from 0 to about 5 mol % of a polymer-conjugated lipid; and (e) from 0 to about 5 mol % of a hydrophobic component; wherein the mol % are based on the total lipids present in the nanoparticle. (I)
Absstract of: WO2026039647A1
Methods of making bioactive compound-loaded nanoparticles are provided. The methods harness naturally-occurring biopolymers to produce nanoparticles from raw plant materials. Methods include contacting plant-derived materials with alkaline solution with agitation to deprotonate the bioactive materials and biopolymers to form nanoparticles. In some forms, the methods contact the nanoparticle with an acid to re-protonate the components and more stable nanoparticles. The bioactive compounds can be extracted from raw plants and/or plant parts, including turmeric, ginger, clove, thyme, pepper, and rosemary. The bioactive compounds include curcumin, gingerols, shogaols, eugenol, thymol, carvacrol, capsaicin, and rosmarinic acid. Compositions and formulations containing bioactive-compound loaded nanoparticles are also provided.
Absstract of: WO2026038042A1
The present invention is directed to peptide modified polymers, nanoparticle compositions comprising peptide modified polymers, nanoparticle compositions comprising a polynucleotide in addition to peptide modified polymers, methods for preparing said peptide modified polymers and nanoparticle compositions, and uses thereof. The polymers can in particular be poly(beta-aminoesters).
Absstract of: WO2026039717A1
Pharmaceutical compositions and compounds comprising a phosphorothioated CpG oligodeoxynucleotide linked to a DNA oligonucleotide that is hybridized an RNA aptamer are useful in methods of treating cancer (such as leukemia) and methods of inhibiting DNA methyltransferase. In embodiments, the RNA aptamer binds to an intracellular target such as DNMT1, NF-kB, RUNX1, MYC, MYB, ETS, PAX5, MDM2, F0XM1, PU.l, STAT3, STATS. STAT6, FAD, ATP5B, or beta-catenin.
Absstract of: WO2026037391A1
A lipid nanoparticle composition targeting to antigen-presenting cells (APCs), comprising: at least a therapeutic agent, at least a cationic or ionizable cationic lipid, at least a neutral lipid, at least a steroid or steroid analogue, at least a PEGylated lipid, and atleast a phosphatidylglycerol.
Absstract of: WO2026039837A1
Generation of lipid nano-particles containing purified human hemoglobin as an oxygen carrier was accomplished with the co-encapsulation of metabolic agents. Additionally, the nano-particles described are of the long-circulating variety (Pegylation of the exterior surface) which are more tolerable in vivo when compared against their non-pegylated counterparts. The generated nano-particles are lyophilizable, given proper formulation with lyo-protectants, which are storage stable solids ready for reconstitution prior to use.
Absstract of: WO2026039800A1
This disclosure relates to polyethylene glycol (PEG) -functionalized nanoparticles comprising a functional agent, and preparation methods, properties and applications thereof. The nanoparticle represented by PEG-L-G/P, comprising a type of hydrophilic PEG, a hydrophobic functional agent G, which are covalently linked by L: a linker or a chemical bond, and a type of hydrophobic polymer P. The G and P form the hydrophobic core, while the PEG constitutes the hydrophilic outer layer of the nanoparticle in an aqueous medium. The functional agent comprises one or more functional compounds including a therapeutic drug, an imaging diagnostic agent, a photoelectric responsive diagnostic agent, an immune-stimulating agent, or a combination thereof. The nanoparticles comprising such functional agent can offer various applications in multiple biomedical fields.
Absstract of: WO2026039075A1
Methods for enhancing CAR-T or CAR-M cell activity by modulating (e.g., activating or inhibiting) cytotoxic activity of the CAR cells over time to speed up or delay killing activity of the cells. Enhanced CAR-T or CAR-M cells prepared according to methods. Therapeutic compositions and treatment methods, such as for treating cancers, using the enhanced CAR-T or CAR-M cells. The enhanced CAR-T or CAR-M cells comprise drug-loaded nanoparticles or nanocarriers comprising a cell-penetrating peptide (WTAS or rp-182) or a fragment thereof and a modified poly(P-amino ester) (PBAE) polymer associated or assembled with one or more cell modulating agents. The cell modulating agents are released into the cytoplasm to thereby modulate the activity of the enhanced CAR-T cells or CAR-M cells.
Absstract of: WO2026038873A1
An iron oxide-ceria nanoparticle, an iron oxide-ceria nanostructure and an iron oxide-ceria nanocomposite are provided. The iron oxide-ceria nanoparticle comprises iron oxide and ceria. The iron oxide-ceria nanostructure comprises an inorganic support and a plurality of iron oxide-ceria nanoparticles dispersed in the inorganic support. The iron oxide-ceria nanocomposite comprises: an inorganic support; a plurality of iron oxide-ceria nanoparticles dispersed in the inorganic support; and a polymer layer that encompasses the inorganic support.
Absstract of: WO2026037345A1
The present disclosure relates to a functionalized targeted branched poly(β-amino ester), a nanoparticle based thereon, a preparation method therefor, and the use thereof. Particularly, the functionalized targeted branched poly(β-amino ester) provided in the present disclosure is capable of effectively delivering biomolecules, particularly functional biomolecules for treating and/or preventing various diseases and conditions.
Absstract of: WO2026036299A1
Provided in the present invention are a steroid-cationic lipid compound having a structure as shown in formula (I) and the use thereof. The compound can be used in the preparation of a lipid nanoparticle (LNP) for delivering a therapeutic agent and/or a preventive agent. The LNP prepared using the steroid-cationic lipid compound of the present invention has relatively good stability and transfection efficiency. The use of the LNP for delivering a nucleic acid, e.g., an mRNA, can realize efficient and stable delivery of biologically active substances to target cells or organs, and can induce a high level of specific antibody responses and cellular immune responses in experimental animals. Moreover, the compound has better safety.
Absstract of: WO2026036296A1
A lipid nanoparticle composition for nucleic acid drug delivery, a preparation method therefor, and use thereof. A composition prepared by mixing a steroid-cationic lipid compound with an auxiliary phospholipid and a polyethylene glycol-modified phospholipid has relatively good stability and transfection efficiency. By using lipid nanoparticles for delivering a nucleic acid, such as mRNA, a nucleic acid drug can be efficiently and stably delivered to a target cell or organ. Moreover, such LNPs can be used for the atomized inhalation administration of mRNA and the development of lyophilized formulations of mRNA. A relatively high specific antibody response can be induced in experimental animals, and the compound has better safety.
Absstract of: US20260048012A1
The present invention concerns a method for the production, purification, and stabilization of plant-derived nanovesicles (PDVs). It also concerns a pharmaceutical composition comprising the PDVs obtained by this method for hypocholesterolemic, hypoglycemic, hypolipidemic, anti-ageing, and antioxidant use.
Absstract of: US20260049286A1
The present disclosure is generally directed to the use of biomaterial scaffolds engineered with SA-FasL for the transplantation of stem cell derived β-cells as a treatment for Type I diabetes. Early engraftment post-transplantation and subsequent maturation of these β-cells may be limited by the initial inflammatory response, which impacts the ability to sustain normoglycemia at long times. The survival and development of immature hPSC-derived β-cells transplanted on poly(lactide-co-glycolide) (PLG) microporous scaffolds into the peritoneal fat, a site being considered for clinical translation, was investigated. The scaffolds were modified with biotin for binding of a streptavidin-FasL (SAFasL) chimeric protein to modulate the local inflammatory microenvironment. The presence of FasL impacted infiltration of monocytes and neutrophils and altered their phenotypic response. Conditioned media generated from scaffolds explanted at day 4 did not impact hPSC-derived β-cell survival and maturation in vitro, which was not observed with unmodified scaffolds. Following transplantation, β-cell viability and differentiation were improved with SA-FasL modification. A sustained increase in insulin positive cell ratio was observed with SA-FasL modified relative to unmodified scaffolds. These results demonstrate that SA-FasL-modified scaffolds can mitigate initial inflammatory response and enhance β-cell engraftment and differentiation.
Absstract of: US20260049162A1
Chitosan nanoparticles include chitosan and more than one lasso peptide, wherein the lasso peptide has a carboxyl group; an amino group in the structure of the chitosan is connected to the carboxyl group of the lasso peptide via an amide bond.
Absstract of: US20260049154A1
An immuno-nanolipoprotein particle (Immuno-NLP) comprising one or more membrane forming lipids, a scaffold protein and an immune cell transmembrane protein, and methods of using immuno-nanolipoprotein particles to deliver immune cell transmembrane protein to immune cells, and related compositions, methods, and systems.
Absstract of: US20260048152A1
The present invention relates to an inorganic-organic hybrid compound as ionic compound, composed of an inorganic metal cation selected from ZrO2+, and of an organic active ingredient anion selected from gemcitabine monophosphate or gemcitabine triphosphate.
Absstract of: US20260048142A1
The disclosure relates to the technical field of biological medicines, and particularly provides a metal-chelated polyphenol complex nanoparticle, a drug-lipid particle, preparation methods for the same, and the uses thereof. The present disclosure provides a metal-chelated polyphenol complex as a carrier for drugs for stability, delivery and the like, so that it interacts with other carriers to form a metal-chelated polyphenol complex nanoparticle for effective administration of negatively charged drug. High-efficiency systemic drug delivery can be achieved, while toxicity is significantly reduced compared to LNP containing cationic or ionizable lipids, enabling safe and effective treatment of diseases or disorders.
Absstract of: US20260048141A1
This disclosure relates to polyethylene glycol (PEG)-functionalized nanoparticles comprising a functional agent, and preparation methods, properties and applications thereof. The nanoparticle represented by PEG-L-G/P, comprising a type of hydrophilic PEG, a hydrophobic functional agent G, which are covalently linked by L: a linker or a chemical bond, and a type of hydrophobic polymer P. The G and P form the hydrophobic core, while the PEG constitutes the hydrophilic outer layer of the nanoparticle in an aqueous medium. The functional agent comprises one or more functional compounds including a therapeutic drug, an imaging diagnostic agent, a photoelectric responsive diagnostic agent, an immune-stimulating agent, or a combination thereof. The nanoparticles comprising such functional agent can offer various applications in multiple biomedical fields.
Absstract of: US20260048128A1
The subject invention pertains to a novel composition comprising a self-therapeutic metal nanoparticle core coated with a hydrophilic polymer, and optionally a therapeutic agent linked to the polymer. The linker comprises functional groups that can bind to both the metal core and the polymer. The subject invention further discloses a method for treating HD in a subject comprising administering an effective amount of the composition to a subject with HD. The composition exhibits self-therapeutic properties when administered to patients with Huntington's disease. Additionally, the invention comprises a method for synthesizing gold nanoparticles for treating Huntington's disease. This method comprises conjugating gold nanoparticles with polyethylene glycol (PEG) and attaching a therapeutic agent via a linker to the PEG. This enables targeted delivery of the therapeutic agent to its therapeutic targets.
Absstract of: US20260048118A1
Compositions for improved gene editing and methods of use thereof are disclosed. In a preferred method, gene editing involves use of a cell-penetrating anti-DNA antibody, such as 3E10, as a potentiating agent to enhance gene editing by nucleases and triplex forming oligonucleotides. Genomic modification occurs at a higher frequency when cells are contacted with the potentiating agent and nuclease or triplex forming oligonucleotide, as compared to the absence of the potentiating agent. The methods are suitable for both ex vivo and in vivo approaches to gene editing and are useful for treating a subject with a genetic disease or disorder. Nanoparticle compositions for intracellular delivery of the gene editing compositions are provided and are particularly advantageous for use with in vivo applications.
Absstract of: US20260048022A1
A novel targeting process and nanoparticle design is disclosed, improving delivery of drugs and other pay load materials to tumors and other sites of interest. In a preferred embodiment, endothelial cells are damaged at the target site, thereby activating platelets. Nanoparticles bearing fibrinogen or other materials that bind to activated platelets are administered that also contain one or more drugs or other pay load substances thereby improving payload delivery to the targeted site.
Absstract of: US20260048014A1
The present invention is related to the field of targeted drug delivery. In particular, the particles and compositions described herein are used to deliver drugs to treat the diseases and conditions of interest. These particles and compositions include, but are not limited to, the lipopeptide complexes that mimic human high-density lipoproteins but contain apolipoprotein fragments or combination thereof.
Nº publicación: US20260048140A1 19/02/2026
Applicant:
KOWA COMPANY LTD [JP]
KOWA COMPANY, LTD
Absstract of: US20260048140A1
A copolymer in which a target-affinity molecule is bonded to a copolymer X having structural units of (A), (B), and (C):R1, R2, and R3 are the same or different and are hydrogen or C1-3 alkyl. R4 is C1-3 alkyl. R5 is hydrogen, C1-18 alkyl, 3- to 8-membered cycloalkyl optionally having a substituent, adamantyl, C6-18 aryl optionally having a substituent, or a 5- to 10-membered heteroaryl optionally having a substituent. X1, X2, and X3 are the same or different and are oxygen, sulfur, or N—R7. R6 is hydrogen, a leaving group, or a linker. R7 is hydrogen or C1-3 alkyl. m is a number of 1 to 100, and n is 0 to 3.
BOPI
Electronic site
